BioSpace News Archive

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022 Closed $80 million private placement of common stock financing with new and existing investors Cash runway into second half of 2023 and through readout of Phase 3 clinical trials and potential NDA filing by end of 2022

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules

Deutsche Bank announced its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited.

Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters’ overallotment option to purchase 545,454 additional shares of common stock, at a public offering price of $11.00 per share

Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely